Stock Financial Ratios, Dividends, Split History

AMTD / TD AmeriTrade Holding Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)33,701.87
Enterprise Value ($M)34,588.87
Book Value ($M)7,595.00
Book Value / Share13.38
Price / Book4.53
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 529,000,000
Common Shares Outstanding 566,939,277
Common Stock Shares Outstanding 567,000,000
Weighted Average Number Of Diluted Shares Outstanding 531,000,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.09
Return on Assets (ROA)0.03
Return on Equity (ROE)0.17
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Asset Based Revenues12,220,000,000.00
Brokerage Commissions Revenue1,384,000,000.00
Asset Based Revenues1,113,000,000.00
Operating Income1,466.00
Net Income872.00
Earnings Per Share Basic1.65
Earnings Per Share Diluted1.64
Cash Flow Statement (mra) ($M)
Cash From Operations687.00
Cash from Investing-1,547.00
Cash from Financing-1,547.00
Identifiers and Descriptors
Central Index Key (CIK)1173431
Related CUSIPS
087236Y10 87236Y908 87236Y958

Split History

Stock splits are used by TD AmeriTrade Holding Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Fidelity Crypto Is an Experiment Today, But Reality Tomorrow

2018-06-11 investorplace
A few months ago, I was reading Bloomberg Businessweek when I came across a clever TD Ameritrade Holding Corp. (NASDAQ:AMTD) advertisement. It featured a golden bell with the inscription “24/5.” The financial institution sent a clear message: It will offer round-the-clock trading, but limited only to business days. (42-0)

TD Bank Should Be Able To Maintain Its Growth Momentum

2018-06-11 seekingalpha
TD Bank is one of Canada’s largest banks and has significant exposure in the United States. (12-0)

Stocks To Watch: Focus On E3, IHOP/b And The World Cup

2018-06-09 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (639-8)

Stocks To Watch: Focus On E3, IHopb And The World Cup

2018-06-09 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (639-3)

TD Ameritrade Announces Personalized Portfolios: Tailored Investing, Your Way | Business Wire

2018-06-02 businesswire
OMAHA, Neb.--(BUSINESS WIRE)--TD Ameritrade Holding Corporation (Nasdaq: AMTD) is further expanding its investment guidance line-up with the launch of Personalized Portfolios1– a highly customizable managed portfolio solution, giving investors a high-tech, right touch experience that considers their total wealth picture. (11-0)

CUSIP: 87236Y108